Wem sagt denn das was? Ich kann mir da gar nichts drunter vorstellen...
Strong Buy Recommendation Issued For HTTP-Technology At Forefront of New Age in Digital Disease Detection (DDD)
Sherry Grisewood, CFA, who heads our healthcare group, issued her initial report on HTTP Technology on January 16. She noted "HTTP's patent-pending statistical analysis core technology, the Stochastic Perception Engine (SPE), underlies major product opportunities in image analysis,
bio-informatics and other intensive data mining applications, receiving "World Class" validation by the United Kingdom's Defence Evaluation and Research Agency. In medical image analysis, HTTP's Medicsight subsidiary will establish its own scanning centers in Europe and the US. They represent the next generation of detecting, at very early stages, cancer, chronic heart disorders, and other diseases. Its initial disease target, lung caner, has seen virtually no improvement in the 5-year survival rate since the mid-1970s. The Medicsight system greatly improves threshold nodule detection from approximate 7-10 mm for human visual inspection of scans down to 2.5-3mm size nodules. In 2003, its European scanning centers are projected to produce revenues for HTTP of US $15.2 million with EPS of $.02. HTTP is expected to list this year on the AMEX or NASDAQ.
She concluded with a 12-month $7 price target (report price: $3.80) for this $220 million market cap leading DDD company. Disease detection and treatment will change significantly as earlier disease detection occurs. We strongly urge you to read her report for her discussion of the next phase of
new disease detection systems.
Strong Buy Recommendation Issued For HTTP-Technology At Forefront of New Age in Digital Disease Detection (DDD)
Sherry Grisewood, CFA, who heads our healthcare group, issued her initial report on HTTP Technology on January 16. She noted "HTTP's patent-pending statistical analysis core technology, the Stochastic Perception Engine (SPE), underlies major product opportunities in image analysis,
bio-informatics and other intensive data mining applications, receiving "World Class" validation by the United Kingdom's Defence Evaluation and Research Agency. In medical image analysis, HTTP's Medicsight subsidiary will establish its own scanning centers in Europe and the US. They represent the next generation of detecting, at very early stages, cancer, chronic heart disorders, and other diseases. Its initial disease target, lung caner, has seen virtually no improvement in the 5-year survival rate since the mid-1970s. The Medicsight system greatly improves threshold nodule detection from approximate 7-10 mm for human visual inspection of scans down to 2.5-3mm size nodules. In 2003, its European scanning centers are projected to produce revenues for HTTP of US $15.2 million with EPS of $.02. HTTP is expected to list this year on the AMEX or NASDAQ.
She concluded with a 12-month $7 price target (report price: $3.80) for this $220 million market cap leading DDD company. Disease detection and treatment will change significantly as earlier disease detection occurs. We strongly urge you to read her report for her discussion of the next phase of
new disease detection systems.
